In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.8% to 8,629.8 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are pushing higher:
Image source: Getty Images
Auckland International Airport Ltd (ASX: AIA)
The Auckland International Airport share price is up 4.5% to $7.09. Investors have been buying the airport operator's shares after it released an update. According to the release, the Ministry of Business Innovation and Employment (MBIE) has advised that it is not considering legislative change in respect to "the effectiveness of the economic regulation of airport services under Part 4 of the Commerce Act 1986."
Australian Ethical Investment Ltd (ASX: AEF)
The Australian Ethical share price is up 3% to $6.42. This follows the release of a fourth quarter and full year update from the fund manager. Australian Ethical revealed that it achieved a 34% increase in funds under management (FUM) to a record high of $13.94 billion in FY 2025. Commenting on its performance, the company's CEO, John McMurdo, said: "Our strong fourth quarter result, and our full year FUM growth of 34% reflects the ongoing disciplined execution of our strategy as well as the resilience of our ethical investment approach in the face of challenging economic and geo-political cycles."
Breville Group Ltd (ASX: BRG)
The Breville Group share price is up 3% to $30.65. This appears to have been driven by a broker note out of UBS this morning. According to the note, the broker has upgraded this appliance manufacturer's shares to a buy rating with an improved price target of $35.50. UBS made the move after looking at the global coffee machine market. It feels that the stage is set for Breville to grow its sales materially over the next decade. Especially given its significant opportunity in new markets.
Clarity Pharmaceuticals Ltd (ASX: CU6)
The Clarity Pharmaceuticals share price is up 4% to $3.55. This morning, this radiopharmaceutical company announced that the Co-PSMA (NCT06907641) Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent's Hospital Sydney has now completed its study enrolment and all participants have been imaged. Clarity's executive chair, Dr Alan Taylor, said: "We are excited about this important milestone in the Co-PSMA trial and the development program of 64Cu-SAR-bisPSMA. With mounting data of the benefits that 64Cu-SAR-bisPSMA could offer compared to SOC diagnostic imaging, demonstrated in the PROPELLER and COBRA trials, we eagerly anticipate the results from this head-to-head trial against 68Ga-PSMA-11."
